You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Measles Seropositivity in HIV-infected Kenyan Children on Antiretroviral Therapy

Newman, Laura P. MHS*; Njoroge, Anne MBChB; Ben-Youssef, Leila MD, MA; Merkel, Michele MS‡§; Gatuguta, Ann MBChB, MPH; Ton, Quy MD, MPH; Obimbo, Elizabeth Maleche MBChB, MMed, MPH; Wamalwa, Dalton MBChB, MMed, MPH; Lohman-Payne, Barbara PhD, MSc‡§¶; Richardson, Barbra A. PhD, MS¶‖**; Nduati, Ruth MBChB, MMed, MPH§; Farquhar, Carey MD, MPH*‡¶

Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0000000000000332
HIV Reports
Abstract

This article describes results from a cross-sectional study among HIV-infected children 15 months to 12 years of age who were receiving antiretroviral therapy. We found a low prevalence of measles IgG seropositivity (45.7%) and identified CD4% ≥ 25 as a predictor. Most HIV-infected children on ART were not measles seropositive and might benefit from revaccination.

Author Information

From the *Department of Epidemiology, University of Washington, Seattle, WA; Department of Public Health, University of Nairobi, Nairobi, Kenya; Department of Medicine, University of Washington, Seattle, WA: §Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya; Departments of Global Health and Biostatistics, University of Washington; and **Division of Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA.

Accepted for publication January 23, 2014.

Research reported in this publication was supported by the Institute of Allergy and Infectious Disease of the National Institutes of Health under award number K24AI087399. L.P.N. and Q.T. were scholars in the University of Washington International AIDS Research and Training Program (D43TW000007) supported by the NIH Fogarty International Center. L.P.N. also received support from the UW Thomas Francis Jr. Global Health Fellowship. L.B.Y. was supported by Grant Number 5 R24 TW007988 from National Institutes of Health, Fogarty International Center through Vanderbilt University. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, Fogarty International Center and Vanderbilt University. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Laura Newman, Department of Epidemiology, University of Washington, Box 357236, Seattle, WA, 98195, USA. E-mail: lpnewman@u.washington.edu.

© 2014 by Lippincott Williams & Wilkins, Inc.